Premium
Quince Therapeutics Inc (QNCX)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug ... Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.06 | -4 | 1.5 | 1.52 | 1.3 | 229799 | 1.42438424 | CS |
| 4 | 0.02 | 1.40845070423 | 1.42 | 1.6015 | 1.28 | 116422 | 1.42392815 | CS |
| 12 | -0.32 | -18.1818181818 | 1.76 | 2.0397 | 1.28 | 129634 | 1.60013338 | CS |
| 26 | 0.71 | 97.2602739726 | 0.73 | 2.45 | 0.69 | 362923 | 1.46034178 | CS |
| 52 | 0.28 | 24.1379310345 | 1.16 | 2.45 | 0.5116 | 245999 | 1.26556395 | CS |
| 156 | -3.31 | -69.6842105263 | 4.75 | 6.8 | 0.5116 | 412799 | 1.5599207 | CS |
| 260 | -26.59 | -94.8626471638 | 28.03 | 121.98 | 0.5116 | 459165 | 12.69990354 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
